1.18
0.02 (1.72%)
| 前收盘价格 | 1.16 |
| 收盘价格 | 1.18 |
| 成交量 | 101,704 |
| 平均成交量 (3个月) | 176,220 |
| 市值 | 70,935,816 |
| 价格/销量 (P/S) | 26.30 |
| 股市价格/股市净资产 (P/B) | 99.90 |
| 52周波幅 | |
| 利润日期 | 12 Aug 2025 - 18 Aug 2025 |
| 营业利益率 (TTM) | -6,217.44% |
| 稀释每股收益 (EPS TTM) | -3.27 |
| 季度收入增长率 (YOY) | 0.40% |
| 总债务/股东权益 (D/E MRQ) | 6,298.14% |
| 流动比率 (MRQ) | 5.71 |
| 营业现金流 (OCF TTM) | -143.10 M |
| 杠杆自由现金流 (LFCF TTM) | -75.65 M |
| 资产报酬率 (ROA TTM) | -36.78% |
| 股东权益报酬率 (ROE TTM) | -245.59% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | IGM Biosciences, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -3.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.88 |
|
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 37.57% |
| 机构持股比例 | 47.53% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Sanofi | 31 Mar 2025 | 1,438,975 |
| 52周波幅 | ||
| 中 | 1.00 (-15.25%) | |
| 总计 | 1 保留 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Truist Securities | 11 Jun 2025 | 1.00 (-15.25%) | 保留 | 1.27 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合